Status
Conditions
Treatments
About
The purpose of this clinical study is to undertake a pilot safety and efficacy study of a synthetic biodegradable membrane as a substitute for using donor human amniotic membrane (hAM) for the treatment of limbal stem cell deficiency (LSCD) by combining this with freshly excised limbal tissue in theatre as a one stage procedure
Full description
This study will involve the used of a synthetic biodegradable Poly Lactide-co-Glycolic Acid (PLGA) biodegradable, synthetic carrier membrane (PLGA) membrane as a substitute for using donor human amniotic membrane (hAM) for the treatment of limbal stem cell deficiency (LSCD) by combining this with freshly excised limbal tissue in theatre as a one stage procedure.
This has the potential to simplify the current procedure and make it safer and accessible to more surgeons and eventually benefit more patients. The use of PLGA membrane, in place of hAM for limbal transplants, is a novel technique and has a lot of promise and potential, which will potentially benefit patients at large and significantly bring down costs for the limbal transplants while reducing the disease transmission risks of using human donor tissue.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male and female participants who are ≥18 years of age.
Patients having a confirmed diagnosis of total LSCD as confirmed by any one or all of the following:
Participants having unilateral limbal stem cell deficiency due to chemical injury
No prior history of limbal transplantation
No ongoing and other active ocular pathology
No severe pathological and psychological conditions that might interfere with the patients participation in the study
Able to provide written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, for any reason without prejudice.
Exclusion criteria
Bilateral LSCD
LSCD due to autoimmune disorders and partial LSCD
Having other ongoing ocular pathologies and acute ocular inflammation
Previous neoplastic/cancer disease
Severe dry eyes confirmed by Schirmer's test
Acute systemic infections
Prior history of limbal transplantation surgery or multiple surgeries in the limbal region
Substance abuse, medical, psychological or social conditions that may, in the opinion of the investigator, interfere with the patient's participation in the study or evaluation of the study results.
Any uncontrolled, inter-current illness that in the opinion of the Investigator may interfere with study evaluation.
Participants with uncontrolled diabetes will be excluded from the study
History or evidence of cardiac disease: congestive heart failure; New York Heart Association (NYHA) class 2 or greater (see Appendix 6); active coronary artery disease; unstable angina, cardiac arrhythmias requiring anti-arrhythmic therapy, atrio-ventricular block of second or third degree, or uncontrolled hypertension, patients with recent (less than 6 months) myocardial infarction (MI) or coronary revascularization.
Pregnant and lactating patients, positive urine pregnancy test in women of childbearing potential
Reproductive age patients not practicing effective and adequate birth control measures
Participation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this study.
Previous participation in this study
Primary purpose
Allocation
Interventional model
Masking
5 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal